Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

Affiliations

• ¹ Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, 27710, USA. [email protected].
• ² Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
• ³ Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea.
• ⁴ Scientia Clinical Research, Randwick, NSW, Australia.
• ⁵ Segal Cancer Center, McGill University, Jewish General Hospital, Montreal, QC, Canada.
• ⁶ Princess Margaret Cancer Centre, Toronto, ON, Canada.
• ⁷ Seoul National University Bundang Hospital, Gyeonggi-Do, South Korea.
• ⁸ Honor Health, Scottsdale, AZ, USA.
• ⁹ Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
• ¹⁰ Seoul National University Hospital, Seoul, South Korea.
• ¹¹ Center for Thoracic Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
• ¹² Merck & Co., Inc, Rahway, NJ, USA.
• ¹³ Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA.